GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financi...(rior to AIDS virus infection. The ...),Health

vaccine regimen employs a two-vaccine "prime-boost strategy." Trial

participants will be administered GeoVax HIV-1 DNA vaccine which

"primes" the immune system followed by GeoVax's HIV-1 MVA (Modified

Vaccinia Virus) boost. Both vaccines deliver over 50% of the AIDS virus

components but can not cause AIDS. Safety and immunological results

from earlier as well as ongoing human trials are very encouraging thus

supporting planned acceleration of large scale Phase 2 clinical

studies.

-- In September, GeoVax announced receipt of an estimated $15 million

Integrated Preclinical/Clinical AIDS Vaccine Development [IPCAVD] Grant

to support its HIV/AIDS vaccine program. This large Grant was awarded

by the National Institutes of Health-National Institute of Allergy &

Infectious Disease [NIH-NIAID], an agency of the U.S. Government. The

grant funding period is over a five year period commencing October

2007. Only meritorious HIV/AIDS prevention vaccine candidates are

considered to receive an IPCAVD award. Candidate companies are highly

scrutinized and must supply substantial positive AIDS vaccine data to

support their application. IPCAVD grants are awarded on a competitive

basis and are designed to support later stage vaccine research,

development and human trials. GeoVax will utilize this funding to

further its HIV/AIDS vaccine development, optimization, production and

human clinical trial testing.

GeoVax announced in January 2008 that it had been recognized by Georgia

Bio, the state trade organization, as a 2007 "Deal of the Year" award

winner for receipt of the $15 million IPCAVD grant.

-- In September, GeoVax announced the presentation of successful human

trial results for its HIV/AIDS vaccines at the
'/>"/>